These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 14693298)

  • 1. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Wellington K; Goa KL
    Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
    Major PP; Coleman RE
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
    Neville-Webbe Hl; Coleman RE
    Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
    Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
    J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
    Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid.
    Cheer SM; Noble S
    Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.